Table 4. Risk factors for developing... | American Society of Hematology

Table 4.

Risk factors for developing myelodysplastic syndrome in patients with aplastic anemia by univariate analysis

Variable	Relative risk (95% CI)	P
Age	0.96 (0.85-1.09)	.57
Sex, female	0.72 (0.21-2.37)	.58
Severity of disease
Moderate	1.00
Severe	1.54 (0.40-5.97)	.53
Very severe	0.44 (0.09-2.63)	.44
No response to therapy at 6 mo	5.41 (1.90-15.4)	.002
Number of days of G-CSF therapy^4-150	1.003 (1.002-1.006)	.0001
Less than 120 d	1.00
120 d or more	4.44 (1.33-14.8)	.02
Number of days of CyA therapy^4-150	1.000 (0.999-1.001)	.86
Less than 360 d	1.00
360 d or more	0.81 (0.26-2.52)	.72
Number of days of DAN therapy^4-150	1.000 (0.999-1.001)	.64
Less than 360 d	1.00
360 d or more	1.93 (0.58-6.42)	.28
History of previous therapies	7.39 (2.33-23.8)	.0007
History of G-CSF therapy before registration	10.3 (3.25-32.8)	.0001
Second ATG therapy	0.49 (0.06-3.80)	.50

Variable	Relative risk (95% CI)	P
Age	0.96 (0.85-1.09)	.57
Sex, female	0.72 (0.21-2.37)	.58
Severity of disease
Moderate	1.00
Severe	1.54 (0.40-5.97)	.53
Very severe	0.44 (0.09-2.63)	.44
No response to therapy at 6 mo	5.41 (1.90-15.4)	.002
Number of days of G-CSF therapy^4-150	1.003 (1.002-1.006)	.0001
Less than 120 d	1.00
120 d or more	4.44 (1.33-14.8)	.02
Number of days of CyA therapy^4-150	1.000 (0.999-1.001)	.86
Less than 360 d	1.00
360 d or more	0.81 (0.26-2.52)	.72
Number of days of DAN therapy^4-150	1.000 (0.999-1.001)	.64
Less than 360 d	1.00
360 d or more	1.93 (0.58-6.42)	.28
History of previous therapies	7.39 (2.33-23.8)	.0007
History of G-CSF therapy before registration	10.3 (3.25-32.8)	.0001
Second ATG therapy	0.49 (0.06-3.80)	.50

CI indicates confidence interval; G-CSF, granulocyte colony-stimulating factor; CyA, cyclosporin; DAN, danazol; ATG, antithymocyte globulin.

As a continuous variable.